SMS Pharmaceuticals to host investor meet with Emkay Global

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • SMS Pharmaceuticals will hold an investor meet on September 15, 2026
  • The group meeting is scheduled with Emkay Global Investors
  • Venue is Hyderabad for the analyst interaction
  • No unpublished price-sensitive information will be discussed
powered bylight_fuzz_icon
50580112

*this image is generated using AI for illustrative purposes only.

SMS Pharmaceuticals will host a group analyst and institutional investor meeting in Hyderabad on September 15, 2026. The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The interaction is scheduled with Emkay Global Investors. Management confirmed that discussions will focus on industry and company-specific developments already in the public domain. No unpublished price-sensitive information will be shared during the session.

Meeting Details

Date Venue Nature of Meeting Counterparty
September 15, 2026 Hyderabad Group meet Emkay Global Investors

The company noted that the schedule remains subject to change due to exigencies involving the analysts, investors, or the firm itself. Thirumalesh Tumma, Company Secretary, signed the disclosure filed with the BSE and NSE on September 10, 2026.

Historical Stock Returns for SMS Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+11.02%+23.87%+24.62%+10.27%+72.91%0.0%

How might the insights shared by SMS Pharmaceuticals regarding industry trends influence its near-term stock valuation and investor sentiment?

What specific strategic initiatives or pipeline developments might SMS Pharmaceuticals highlight to justify future growth to institutional investors?

Could this meeting signal an upcoming regulatory filing or product launch that has not yet been publicly disclosed?

SMS Pharmaceuticals schedules 38th AGM for September 29 via video conference

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • SMS Pharmaceuticals schedules its 38th AGM for September 29, 2026
  • The meeting will be held via video conferencing without physical presence
  • Remote e-voting runs from September 25 to September 28, 2026
  • Record date for dividend eligibility is fixed at September 22, 2026
  • Book closure period extends from September 23 to September 29, 2026
powered bylight_fuzz_icon
50150730

*this image is generated using AI for illustrative purposes only.

SMS Pharmaceuticals has scheduled its 38th Annual General Meeting for Tuesday, September 29, 2026. The event will be conducted through Video Conferencing or Other Audio Visual Means, adhering to Ministry of Corporate Affairs and SEBI guidelines.

The meeting is set to begin at 10:30 am. Shareholders will transact ordinary and special business, including the approval of financial statements for the fiscal year ended March 31, 2026.

Voting and Record Dates

Remote e-voting facilities will be available from Friday, September 25, 2026, at 9:00 am until Monday, September 28, 2026, at 5:00 pm. Central Depository Services Limited (CDSL) has been appointed as the agency to facilitate electronic voting.

Key Date Detail
AGM Date September 29, 2026
E-voting Start September 25, 2026
E-voting End September 28, 2026
Record Date September 22, 2026
Book Closure September 23-29, 2026

Only members whose names appear in the Register of Members as of the cut-off date, September 22, 2026, are eligible to vote. The Register of Members and Share Transfer Books will remain closed from September 23 to September 29, 2026, inclusive.

Dividend Eligibility

The company has fixed September 22, 2026, as the record date for determining eligibility for dividends on equity shares, subject to approval at the AGM. Shareholders are advised to update their KYC and bank account details with their Depository Participants to ensure direct receipt of dividends.

Historical Stock Returns for SMS Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+11.02%+23.87%+24.62%+10.27%+72.91%0.0%

What specific financial performance metrics or strategic initiatives will be highlighted in the FY2026 results presented at the AGM?

How might the proposed dividend payout ratio impact SMS Pharmaceuticals' future capital allocation and R&D investment plans?

Are there any special resolutions regarding executive compensation, board restructuring, or new share issuances scheduled for shareholder approval?

More News on SMS Pharmaceuticals

1 Year Returns:+72.91%